FIELD: medicine.
SUBSTANCE: present invention relates to the treatment of borderline personality disorder. Disclosed is a method of treating borderline personality disorder in a patient by treating one or more non-aggressive symptoms of borderline personality disorder, which involves administering to the patient a therapeutically effective amount of a KDM1A inhibitor, which is 5-(((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazole-2-amine or a pharmaceutically acceptable salt or solvate thereof. Also described is the use of said KDM1A inhibitor for treating borderline personality disorder, as well as for preparing a medicinal agent based thereon.
EFFECT: invention provides treating one or more non-aggressive symptoms of borderline personality disorder.
12 cl, 3 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF BEHAVIOR CHANGES | 2018 |
|
RU2799049C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2010 |
|
RU2602814C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS USING LSD1 INHIBITOR | 2017 |
|
RU2768120C2 |
| LYSINE-SPECIFIC HISTONE DEMETHYLASE 1A (KDM1A) INHIBITORS FOR DISEASE THERAPY | 2019 |
|
RU2813145C2 |
| COMBINATION OF IADADEMSTAT FOR TREATING CANCER | 2020 |
|
RU2833564C2 |
| COMPOSITIONS AND METHODS OF TREATING DISEASES AND CONDITIONS | 2015 |
|
RU2713886C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
